Efficacy of Deferasirox (Exjade®) versus Osveral® in Treatment of Iron Overload in Patients with Beta- thalassemia Major in Iran; A Non-randomized Controlled Trial
Journal Title: Iranian Journal of Blood and Cancer - Year 2016, Vol 8, Issue 4
Abstract
Background: Iron chelators are an important part of management of patients with thalassemia. It is prudent to compare efficacy of different iron chelators in treatment of iron overload in these patients who receive regular blood transfusion. We aimed to compare the efficacy and safety of available oral iron chelator; Deferasirox (Exjade®) with Deferasirox (Osveral®) in reducing iron overload in patients with β-thalassemia major. Methods: Children suffering from β-thalassemia major referring to Mofid Children Hospital were enrolled in this non-randomized clinical trial. The patients were divided into two groups receiving Deferasirox (Exjade®) versus Deferasirox (Osveral®) and their response to either treatment was assessed by measurement of serum ferritin levels and estimation of cardiac and liver iron by MRI T2* of heart and liver. Efficacy of either medication was compared before and after 12 months of treatment. Serum ferritin levels were measured every three months. Mean serum ferritin at baseline was compared with post-treatment values. MRI T2* of heart and liver was performed before and after treatment. Results: Out of 69 patients with a mean age of 13.6±7.4 years, 42 (60.9%) were male. 30 patients were assigned to take Deferasirox (Exjade®) and 39 patients to take Deferasirox (Osveral®). The groups were not different regarding the age and the gender (P=0.18 and 0.621, respectively). There was no statistically significant difference in post-treatment serum ferritin level measurements between the two groups. In patients who received Osveral®, decrease in liver iron overload was significant (0.99 ms in Exjade® group vs 1.16 ms in Osveral® group, p=0.007). In the group of patients who received Exjade®, decrease in cardiac iron overload was significant (4.52 in Exjade group vs. 1.71 in Osveral group, P<0.001). Conclusion: Deferasirox (Osveral®), the iron chelator manufactured in Iran, was as efficient as Deferasirox (Exjade®) in iron removal and could be a substitute for Deferasirox (Exjade®).
Authors and Affiliations
Neda Ashayeri, Elham Sadeghi, Sara Sadeghi, Peyman Eshghi, Samin Alavi
Keywords
Related Articles
- EP ID EP248720
- DOI -
- Views 112
- Downloads 0
Recombinant Human Erythropoietin in Children with Solid Tumors and Chemotherapy-induced Anemia
Background: In patients undergoing chemotherapy for cancer, anemia is part of the progression of the disease. Considering the effects of anemia on quality of life of the patients, the prevention and treatment of chemothe...
Occult Hepatitis B Infection and Its Role in Blood Safety: a Review
Background: Blood transfusion plays a great role in public health and the blood safety still has remained a main concern. HBV has been considered as one of the most prevalent blood borne infections. It is estimated that...
Molecular Markers in Neuroblastoma
Neuroblastoma, one of the common malignant childhood tumors, arises from neuroblast cells derived from the neural crest and destined for the adrenal medulla and the sympathetic nervous system and shows remar...
Main Determinants of Severe Neutropenia in Patients with Solid Tumors Receiving Adjuvant Chemotherapy
Background:Chemotherapy-induced neutropenia as a major toxicity of systemic chemotherapy is commonly associated with substantial mortality and morbidity, and thus identifying its determinants is necessary. This study was...
Patterns of Gelatinase-B Expression in Leukemic Cell Lines
Background: Gelatinase-B named MMP-9 (matrix metalloproteinase-9), is a protease that degrades collagen type ІV and V of extracellular matrix. MMP-9 production is increased in various types of cancers including leukemia...